QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.005728v1 67/5/1505    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Charlier, H. A. Articles by Shadle, S. E. Search for Related Content PubMed PubMed Citation Articles by Charlier, H. A., Jr. Articles by Shadle, S. E.

ORIGINAL ARTICLE

Investigations of Calsequestrin as a Target for Anthracyclines: Comparison of Functional Effects of Daunorubicin, Daunorubicinol, and Trifluoperazine

Department of Chemistry, Boise State University, Boise, Idaho (H.A.C., C.M.T., W.K.M., T.S.B., D.J.M., C.L.L., S.E.S.); Mountain States Tumor and Medical Research Institute, Boise, Idaho (H.A.C., R.D.O., B.J.C., S.E.S.); School of Medicine, University of Washington, Seattle, Washington (R.D.O., B.J.C., S.E.S.); and Research Service, Department of Veterans Affairs Medical Center, Boise, Idaho (R.D.O., D.R.O., B.J.C.)

Abstract

Anthracycline therapy is associated with a life-threatening but poorly understood cardiotoxicity. Effects of treatment are consistent with drug-induced disruption of cardiac sarcoplasmic reticulum (SR) calcium homeostasis, including inhibition of calcium release by anthracyclines. This effect, which depends on luminal SR calcium concentration, is hypothesized to involve interactions of anthracyclines with the calcium binding protein calsequestrin (CSQ). This study was designed to test the hypothesis that an interaction between CSQ and anthracyclines could be related to alterations in SR calcium release and cardiac function. The effects of the anthracycline, daunorubicin, and its metabolite daunorubicinol were compared with those of a known CSQ inhibitor, trifluoperazine (TFP). Protein fluorescence quenching studies demonstrated that TFP, daunorubicin, and daunorubicinol bind to CSQ with apparent binding affinities in the low micromolar range. The presence of calcium decreases the drug-dependent fluorescence quenching, probably because of calcium-induced CSQ conformational changes. TFP also inhibited SR calcium release. Although the TFP IC₅₀ value is somewhat larger than for anthracyclines, the TFP effect is also dependent on luminal SR calcium concentration. In a muscle preparation, micromolar TFP decreased cardiac contractility in a manner that implicates the involvement of SR calcium and resembles the effects of anthracyclines. These data are consistent with a mechanism in which TFP or anthracyclines impair SR calcium release and cardiac function through a mechanism involving disruption of CSQ function. Such a mechanism may contribute to anthracycline cardiotoxicity.

Address correspondence to: Dr. Susan E. Shadle, Department of Chemistry, MS 1520, Boise State University, 1910 University Dr., Boise, ID 83725. E-mail: sshadle{at}chem.boisestate.edu

This article has been cited by other articles:

				E. Salvatorelli, P. Menna, L. Gianni, and G. Minotti Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 790 - 800. [Abstract] [Full Text] [PDF]

				E. Salvatorelli, S. Guarnieri, P. Menna, G. Liberi, A. M. Calafiore, M. A. Mariggio, A. Mordente, L. Gianni, and G. Minotti Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart: RELATIVE IMPORTANCE OF VESICULAR SEQUESTRATION AND IMPAIRED EFFICIENCY OF ELECTRON ADDITION J. Biol. Chem., April 21, 2006; 281(16): 10990 - 11001. [Abstract] [Full Text] [PDF]

				E. Kim, M. Tam, W. F. Siems, and C. Kang Effects of Drugs with Muscle-Related Side Effects and Affinity for Calsequestrin on the Calcium Regulatory Function of Sarcoplasmic Reticulum Microsomes Mol. Pharmacol., December 1, 2005; 68(6): 1708 - 1715. [Abstract] [Full Text] [PDF]